Discovery of Novel Small-Molecule Inhibitors of SARS-CoV-2 Main Protease as Potential Leads for COVID-19 Treatment

被引：17

作者：

Manandhar, Anjela ^{[1
,2
]}

Srinivasulu, Vunnam ^{[3
]}

Hamad, Mohamad ^{[3
]}

Tarazi, Hamadeh ^{[4
]}

Omar, Hany ^{[3
,4
]}

Colussi, Dennis J. ^{[5
]}

Gordon, John ^{[5
]}

Childers, Wayne ^{[5
]}

Klein, Michael L. ^{[1
,2
]}

Al-Tel, Taleb H. ^{[3
,4
]}

Abou-Gharbia, Magid ^{[5
]}

Elokely, Khaled M. ^{[1
,2
,6
]}

机构：

[1] Temple Univ, Inst Computat Mol Sci, Philadelphia, PA 19122 USA

[2] Temple Univ, Dept Chem, Philadelphia, PA 19122 USA

[3] Univ Sharjah, Sharjah Inst Med Res, Sharjah 27272, U Arab Emirates

[4] Univ Sharjah, Coll Pharm, Sharjah 27272, U Arab Emirates

[5] Temple Univ, Moulder Ctr Drug Discovery Res, Sch Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19122 USA

[6] Tanta Univ, Dept Pharmaceut Chem, Tanta 31527, Egypt

来源：

JOURNAL OF CHEMICAL INFORMATION AND MODELING | 2021年 / 61卷 / 09期

基金：

美国国家科学基金会;

关键词：

DYNAMICS; SARS; IDENTIFICATION; DESIGN; PREDICTION; DOCKING;

D O I：

10.1021/acs.jcim.1c00684

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The main protease of SARS-CoV-2 virus, M-pro is an essential element for viral replication, and inhibitors targeting M-pro are currently being investigated in many drug development programs as a possible treatment for COVID-19. An in vitro pilot screen of a highly focused collection of compounds was initiated to identify new lead scaffolds for M-pro. These efforts identified a number of hits. The most effective of these was compound SIMR-2418 having an inhibitory IC50 value of 20.7 mu M. Molecular modeling studies were performed to understand the binding characteristics of the identified compounds. The presence of a cyclohexenone warhead group facilitated covalent binding with the Cys(145) residue of M-pro. Our results highlight the challenges of targeting M-pro protease and pave the way toward the discovery of potent lead molecules.

引用

页码：4745 / 4757

页数：13

共 50 条

[21] Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19
Liu, Hengrui
Iketani, Sho
Zask, Arie
Khanizeman, Nisha
Bednarova, Eva
Forouhar, Farhad
Fowler, Brandon
Hong, Seo Jung
Mohri, Hiroshi
Nair, Manoj S.
Huang, Yaoxing
Tay, Nicholas E. S.
Lee, Sumin
Karan, Charles
Resnick, Samuel J.
Quinn, Colette
Li, Wenjing
Shion, Henry
Xia, Xin
Daniels, Jacob D.
Bartolo-Cruz, Michelle
Farina, Marcelo
Rajbhandari, Presha
Jurtschenko, Christopher
Lauber, Matthew A.
McDonald, Thomas
Stokes, Michael E.
Hurst, Brett L.
Rovis, Tomislav
Chavez, Alejandro
Ho, David D.
Stockwell, Brent R.
NATURE COMMUNICATIONS, 2022, 13 (01)
[22] In silico Screening of Natural Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike RBD: Targets for COVID-19
Teli, Divya M.
Shah, Mamta B.
Chhabria, Mahesh T.
FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 7
[23] The COVID-19 pandemic and the potential treatment of the novel coronavirus SARS-CoV-2
Wang, Shilei
Ye, Jinlei
Kang, Zhichao
Peng, Hongmei
Mackey, Vienna
Sun, Lichun
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (03): : 871 - 881
[24] Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19
Lu, Yongzhi
Yang, Qi
Ran, Ting
Zhang, Guihua
Li, Wenqi
Zhou, Peiqi
Tang, Jielin
Dai, Minxian
Zhong, Jinpeng
Chen, Hua
He, Pan
Zhou, Anqi
Xue, Bao
Chen, Jiayi
Zhang, Jiyun
Yang, Sidi
Wu, Kunzhong
Wu, Xinyu
Tang, Miru
Zhang, Wei K.
Guo, Deyin
Chen, Xinwen
Chen, Hongming
Shang, Jinsai
NATURE COMMUNICATIONS, 2024, 15 (01)
[25] Discovery of Small-Molecule Inhibitors of SARS-CoV-2 Proteins Using a Computational and Experimental Pipeline
Lau, Edmond Y.
Negrete, Oscar A.
Bennett, W. F. Drew
Bennion, Brian J.
Borucki, Monica
Bourguet, Feliza
Epstein, Aidan
Franco, Magdalena
Harmon, Brooke
He, Stewart
Jones, Derek
Kim, Hyojin
Kirshner, Daniel
Lao, Victoria
Lo, Jacky
McLoughlin, Kevin
Mosesso, Richard
Murugesh, Deepa K.
Saada, Edwin A.
Segelke, Brent
Stefan, Maxwell A.
Stevenson, Garrett A.
Torres, Marisa W.
Weilhammer, Dina R.
Wong, Sergio
Yang, Yue
Zemla, Adam
Zhang, Xiaohua
Zhu, Fangqiang
Allen, Jonathan E.
Lightstone, Felice C.
FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
[26] Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2
Su, Hailei
Zhou, Feng
Huang, Ziru
Ma, Xiaohua
Natarajan, Kathiresan
Zhang, Minchuan
Huang, Yong
Su, Haibin
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2021, 60 (18) : 9789 - 9802
[27] Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2
Abel, Renata
Ramos, Maria Paredes
Chen, Qiaofeng
Perez-Sanchez, Horacio
Coluzzi, Flaminia
Rocco, Monica
Marchetti, Paolo
Mura, Cameron
Simmaco, Maurizio
Bourne, Philip E.
Preissner, Robert
Banerjee, Priyanka
FRONTIERS IN CHEMISTRY, 2020, 8
[28] Computational Determination of Potential Inhibitors of SARS-CoV-2 Main Protease
Son Tung Ngo
Ngoc Quynh Anh Pham
Ly Thi Le
Duc-Hung Pham
Vu, Van V.
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2020, 60 (12) : 5771 - 5780
[29] Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19
Cui, Wen
Yang, Kailin
Yang, Haitao
FRONTIERS IN MOLECULAR BIOSCIENCES, 2020, 7
[30] IN Silico Approach of Some Selected Honey Constituents as SARS-CoV-2 Main Protease (COVID-19) Inhibitors
Hashem, Heba E.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, 2020, 4 (03): : 196 - 200

← 1 2 3 4 5 →